Outcomes of prolonged and low-dose ciclosporin in an Asian population

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

“…1). Full texts of 571 records were assessed, of which 25 met our eligibility criteria 10–34 . Eleven studies were conducted in Europe, 10 in the United States, 2 studies in Asia, 1 in Australia, and 1 study in Mexico.…”

“…In addition to the study by Bosma et al, 25 5 additional studies (2 case reports, 3 cohorts) reported a total of 13 participants with renal disease, including hydronephrosis, renal insufficiency, and end-stage renal disease. 19 , 20 , 25 , 26 , 28 , 31 Three studies examined dupilumab treatment, 20 , 25 , 31 1 study used cyclosporine treatment, 26 1 study examined systemic corticosteroid treatment, 19 and 1 study did not specify the systemic treatment used. 28 Choi et al 26 examined treatment with ciclosporin and reported that 1 patient with chronic kidney disease and 1 patient with end-stage renal failure on dialysis at the start of study, out of 92 patients in total.…”

“… 19 , 20 , 25 , 26 , 28 , 31 Three studies examined dupilumab treatment, 20 , 25 , 31 1 study used cyclosporine treatment, 26 1 study examined systemic corticosteroid treatment, 19 and 1 study did not specify the systemic treatment used. 28 Choi et al 26 examined treatment with ciclosporin and reported that 1 patient with chronic kidney disease and 1 patient with end-stage renal failure on dialysis at the start of study, out of 92 patients in total. Varma et al 31 presented a case report of a 22-month-old patient with a history of hydronephrosis who received 4 weeks of dupilumab.…”

Successful treatment of recalcitrant facial sebopsoriasis with low‐dose cyclosporine

“…Low-dose CysA is increasingly being used as it is not only effective but also associated with a better side-effect profile as compared to higher doses. [2][3][4] Young patients are less likely to have renal side effects as compared to the older age-group.1 Intermittent short courses are also associated with lesser side effects as compared to continuous dosing.5 Our patient experienced gastrointestinal side effects at 3 mg/kg/day and tolerated 1.5 mg/kg/day dose with significant improvement of recalcitrant facial lesions which was maintained even after stopping the therapy.…”

“…Low-dose CysA has been tried in various studies with better clinical outcomes and side effect profile. 1,2 We herein report a novel indication of low-dose oral CysA in the management of recalcitrant facial sebopsoriasis.…”